Skip to main content
Fig. 4 | Journal of Biological Engineering

Fig. 4

From: Design of a prodrug bispecific antibody masked by a functional molecule for lymphocyte activation for cancer therapy

Fig. 4

(a) Confirmation of the cleavage of scFvΔK-MMP-Ex3 using the culture supernatant of MMP-expressing cancer cell lines, HT1080 and A431, using western blotting. Ex3 was detected by horseradish peroxidase (HRP)-conjugated anti-human antibody, and the chemiluminescence was imaged. (b, c) Cancer cell cytotoxicity analysis of Ex3, scFvΔK-MMP-Ex3, and scFv-3C-Ex3 as a negative control. As cancer cell lines, (b) HT1080 and (c) A431 were used, respectively. T-LAK cells were added to cancer cells at a ratio of 5:1 (n = 4). Data are expressed as mean ± SD. The significance of the results was analyzed using one-way ANOVA and followed by Bonferroni’s post hoc test (*p < 0.05; Ex3 vs. scFvΔK-MMP-Ex3)

Back to article page

Journal of Biological Engineering

ISSN: 1754-1611